Wan-Yu Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wan-Yu Chen has a total of 299 co-authors. Here are the top co-authors by number of shared publications:
B S Hsieh
68 shared publicationsT S Yen
64 shared publications- Tun-Jun Tsai
Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
38 shared publications H C Hsu
17 shared publicationsJ T Cheng
12 shared publicationsF W Chen
10 shared publications
Latest Publications
- 27 June 2025
- Published by Wiley in Head & Neck
- Vol. 47 (11) , 3076-3085
Nasopharyngeal Carcinoma in Intensity‐Modulated Radiation Therapy Era: Competing‐Risk Analysis, Recurrence, and Postrecurrence Survival
Background: This study assessed long‐term outcomes in nasopharyngeal carcinoma (NPC) patients treated with modern intensity‐modulated radiation therapy (IMRT), focusing on recurrence patterns and postrecurrence survival (PRS). Methods: A cohort of 1554 NPC patients treated with definitive radiotherapy or concurrent chemoradiotherapy (CCRT) between 2005 and 2019 was analyzed using competing‐risk models. Cumulative incidences of recurrence or death, local recurrence or death, regional recurrence or death, and distant recurrence or death were calculated, with subgroup differences evaluated by Gray's test. PRS was assessed using Kaplan–Meier curves, log‐rank tests, and Cox proportional hazards models. Results: The 3‐, 5‐, and 10‐year cumulative incidences of recurrence or death were 0.143, 0.162, and 0.187. T4 tumors showed poorer local control, and cumulative incidences of distant recurrence or death correlated with N classification. Most recurrences occurred within 2–3 years, with distant recurrences significantly reducing PRS. Conclusion: IMRT provides excellent local‐regional control but requires improvement for T4 tumors and distant recurrences affecting PRS.
- 27 June 2025
- Published by Wiley in Head & Neck
- Vol. 47 (11) , 3076-3085
Nasopharyngeal Carcinoma in Intensity‐Modulated Radiation Therapy Era: Competing‐Risk Analysis, Recurrence, and Postrecurrence Survival
Background: This study assessed long‐term outcomes in nasopharyngeal carcinoma (NPC) patients treated with modern intensity‐modulated radiation therapy (IMRT), focusing on recurrence patterns and postrecurrence survival (PRS). Methods: A cohort of 1554 NPC patients treated with definitive radiotherapy or concurrent chemoradiotherapy (CCRT) between 2005 and 2019 was analyzed using competing‐risk models. Cumulative incidences of recurrence or death, local recurrence or death, regional recurrence or death, and distant recurrence or death were calculated, with subgroup differences evaluated by Gray's test. PRS was assessed using Kaplan–Meier curves, log‐rank tests, and Cox proportional hazards models. Results: The 3‐, 5‐, and 10‐year cumulative incidences of recurrence or death were 0.143, 0.162, and 0.187. T4 tumors showed poorer local control, and cumulative incidences of distant recurrence or death correlated with N classification. Most recurrences occurred within 2–3 years, with distant recurrences significantly reducing PRS. Conclusion: IMRT provides excellent local‐regional control but requires improvement for T4 tumors and distant recurrences affecting PRS.
- Open Access
- 13 January 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 10 (5) , 101716
Knowledge-Based RapidPlan Volumetric Modulated Arc Therapy Model in Nasopharyngeal Carcinoma
- 13 January 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 10 (5) , 101716
Open AccessKnowledge-Based RapidPlan Volumetric Modulated Arc Therapy Model in Nasopharyngeal Carcinoma
- 4 September 2023
- Published by Elsevier in Medical Dosimetry
- Vol. 48 (4) , 304-311
Vertebral artery sparing volumetric modulated arc therapy in nasopharyngeal carcinoma
- 4 September 2023
- Published by Elsevier in Medical Dosimetry
- Vol. 48 (4) , 304-311
Vertebral artery sparing volumetric modulated arc therapy in nasopharyngeal carcinoma
- Open Access
- 11 May 2023
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 24 (9) , e14010
Effect of extended field‐of‐view approaches on the accuracy of stopping power ratio estimation for single‐energy computed tomography simulators
Background: Extended field‐of‐view (eFOV) methods have been proposed to generate larger demonstration FOVs for computed tomography (CT) simulators with a limited scanning FOV (sFOV) size in order to ensure accurate dose calculation and patient collision avoidance. Although the efficacy of these strategies has been evaluated for photon applications, the effect of stopping power ratio (SPR) estimation on proton therapy has not been studied. This study investigated the effect of an eFOV approach on the accuracy of SPR to water estimation in homogeneous and heterogeneous phantoms.Materials and Methods: To simulate patient geometries, tissue‐equivalent material (TEM) and customized extension phantoms were used. The TEM phantom supported various rod arrangements through predefined holes. Images were reconstructed to three FOV sizes using a commercial eFOV technique. A single‐energy CT stoichiometric method was used to generate Hounsfield unit (HU) to SPR (HU‐to‐SPR) conversion curves for each FOV. To investigate the effect of rod location in the sFOV and eFOV regions, eight TEM rods were placed at off‐center distances in the homogeneous phantom and scanned individually. Similarly, 16 TEM rods were placed in the heterogeneous TEM phantom and scanned simultaneously.Results: The conversion curves derived from the sFOV and eFOV data were identical. The average SPR differences of soft‐tissue, bone, and lung materials for rods placed at various off‐center locations were 3.3%, 4.8%, and 39.6%, respectively. In the heterogeneous phantom, the difference was within 1.0% in the absence of extension. However, in the presence of extension, the difference increased to 2.8% for all rods, except for lung materials, whose difference was 4.8%.Conclusions: When an eFOV method is used, the SPR variation in phantoms considerably increases for all TEM rods, especially for lung TEM rods. This phenomenon may substantially increase the uncertainty of HU‐to‐SPR conversion. Therefore, image reconstruction with a standard FOV size is recommended.
- 11 May 2023
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 24 (9) , e14010
Open AccessEffect of extended field‐of‐view approaches on the accuracy of stopping power ratio estimation for single‐energy computed tomography simulators
Background: Extended field‐of‐view (eFOV) methods have been proposed to generate larger demonstration FOVs for computed tomography (CT) simulators with a limited scanning FOV (sFOV) size in order to ensure accurate dose calculation and patient collision avoidance. Although the efficacy of these strategies has been evaluated for photon applications, the effect of stopping power ratio (SPR) estimation on proton therapy has not been studied. This study investigated the effect of an eFOV approach on the accuracy of SPR to water estimation in homogeneous and heterogeneous phantoms.Materials and Methods: To simulate patient geometries, tissue‐equivalent material (TEM) and customized extension phantoms were used. The TEM phantom supported various rod arrangements through predefined holes. Images were reconstructed to three FOV sizes using a commercial eFOV technique. A single‐energy CT stoichiometric method was used to generate Hounsfield unit (HU) to SPR (HU‐to‐SPR) conversion curves for each FOV. To investigate the effect of rod location in the sFOV and eFOV regions, eight TEM rods were placed at off‐center distances in the homogeneous phantom and scanned individually. Similarly, 16 TEM rods were placed in the heterogeneous TEM phantom and scanned simultaneously.Results: The conversion curves derived from the sFOV and eFOV data were identical. The average SPR differences of soft‐tissue, bone, and lung materials for rods placed at various off‐center locations were 3.3%, 4.8%, and 39.6%, respectively. In the heterogeneous phantom, the difference was within 1.0% in the absence of extension. However, in the presence of extension, the difference increased to 2.8% for all rods, except for lung materials, whose difference was 4.8%.Conclusions: When an eFOV method is used, the SPR variation in phantoms considerably increases for all TEM rods, especially for lung TEM rods. This phenomenon may substantially increase the uncertainty of HU‐to‐SPR conversion. Therefore, image reconstruction with a standard FOV size is recommended.
- Open Access
Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion
Hepatocellular carcinoma (HCC) with bile duct invasion is a rare and notorious subtype of HCC. This study included patients that had unresectable HCC with bile duct invasion and proton beam therapy between November 2015 and February 2021. Twenty patients fit the inclusion criteria. The median tumor size was 6.3 cm. Nine patients (45.0%) had major vascular invasions. All included patients received the radiation dose of 72.6 gray relative biological effectiveness due to the proximity of porta hepatis and tumor. The median follow-up time was 19.9 months. The median overall survival was 19.9 months among deceased patients. The 1-year cumulative local recurrence rates were 5.3%, with only two patients developing in-field failure. The 1-year and 2-year overall survival rates were 79.4% and 53.3%. The 1-year progression-free survival was 58.9%. Four patients developed radiation-induced liver disease. The 1-year cholangitis-free survival was 55.0%. Skin toxicity was the most common acute toxicity and rarely severe. Eight patients developed ≤ grade 3 gastrointestinal ulcers. Proton beam therapy offers desirable survival outcomes for unresectable HCC patients with bile duct invasion. Optimal local tumor control could also be obtained within acceptable toxicities.
Open AccessProton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion
Hepatocellular carcinoma (HCC) with bile duct invasion is a rare and notorious subtype of HCC. This study included patients that had unresectable HCC with bile duct invasion and proton beam therapy between November 2015 and February 2021. Twenty patients fit the inclusion criteria. The median tumor size was 6.3 cm. Nine patients (45.0%) had major vascular invasions. All included patients received the radiation dose of 72.6 gray relative biological effectiveness due to the proximity of porta hepatis and tumor. The median follow-up time was 19.9 months. The median overall survival was 19.9 months among deceased patients. The 1-year cumulative local recurrence rates were 5.3%, with only two patients developing in-field failure. The 1-year and 2-year overall survival rates were 79.4% and 53.3%. The 1-year progression-free survival was 58.9%. Four patients developed radiation-induced liver disease. The 1-year cholangitis-free survival was 55.0%. Skin toxicity was the most common acute toxicity and rarely severe. Eight patients developed ≤ grade 3 gastrointestinal ulcers. Proton beam therapy offers desirable survival outcomes for unresectable HCC patients with bile duct invasion. Optimal local tumor control could also be obtained within acceptable toxicities.
- Open Access
- 19 October 2021
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 6 (6) , 1339-1346
Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node
Objective: Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1new in this study).Methods: A total of 243 low/intermediate risk pN1new patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence‐free survival (LRFS), regional recurrence‐free survival (RRFS), and distant metastasis‐free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone.Results: For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5‐year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1new patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1new patients.Conclusion: For low/intermediate risk pN1new patients with oral cavity cancer, adjuvant therapy might be omitted.Level of Evidence: 4.
- 19 October 2021
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 6 (6) , 1339-1346
Open AccessAdjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node
Objective: Whether to administer adjuvant treatment is a matter of great debate for oral cavity cancer harboring a single positive node without extranodal extension and positive margin (defined as low/intermediate risk pN1new in this study).Methods: A total of 243 low/intermediate risk pN1new patients with oral cavity cancer who received curative surgery were included. Overall survival (OS), local recurrence‐free survival (LRFS), regional recurrence‐free survival (RRFS), and distant metastasis‐free survival (DMFS) were compared between patients receiving adjuvant treatment and observation alone.Results: For patients receiving adjuvant therapy vs observation, the differences in outcomes were not statistically significant in terms of 5‐year OS, LRFS, RRFS, and DMFS. For subgroup analysis, in low/intermediate pN1new patients with one or more minor risk factors, adjuvant therapy was not significantly associated with OS, LRFS, RRFS, or DMFS in pN1new patients.Conclusion: For low/intermediate risk pN1new patients with oral cavity cancer, adjuvant therapy might be omitted.Level of Evidence: 4.
- Open Access
- 3 December 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12) , e0225962
Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer
Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are limited. This study aimed to compare the treatment outcomes between definitive chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. Ninety-three N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT may achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Caution should be made to avoid overtreatment for this group of patients.
- 3 December 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12) , e0225962
Open AccessOutcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer
Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are limited. This study aimed to compare the treatment outcomes between definitive chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. Ninety-three N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT may achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Caution should be made to avoid overtreatment for this group of patients.
- Open Access
- 27 March 2019
- Published by MDPI AG in Preprints.org
Less is Enough: Outcome of Bimodality Definitive Concurrent Chemoradiation does not Differ from that of Trimodality Upfront Neck Dissection Followed by Adjuvant Treatment for >6 cm Bulky Lymph Node (N3) Head and Neck Cancer
Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are lacking. This study aimed to compare the treatment outcomes between definitive concurrent chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. 93 N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT can achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Cautions should be made to avoid overtreatment for this group of patients.
- 27 March 2019
- Published by MDPI AG in Preprints.org
Open AccessLess is Enough: Outcome of Bimodality Definitive Concurrent Chemoradiation does not Differ from that of Trimodality Upfront Neck Dissection Followed by Adjuvant Treatment for >6 cm Bulky Lymph Node (N3) Head and Neck Cancer
Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are lacking. This study aimed to compare the treatment outcomes between definitive concurrent chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. 93 N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT can achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Cautions should be made to avoid overtreatment for this group of patients.
- Open Access
- 28 August 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 1-8
Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer
Our aim was to investigate the prognostic significance of tumor-infiltrating lymphocytes (TILs) in operable tongue cancer patients. The presence of CD3+, CD4+, CD8+, and forkhead box protein P3-positive (FOXP3+) TILs in tumor tissues obtained from 93 patients during surgery was examined using immunohistochemistry. The 3-year overall survival (OS) of patients with a low CD8/FOXP3 ratio was significantly lower than that of patients with a high CD8/FOXP3 ratio (63.8% vs. 87.3%, p = 0.001). Patients with high FOXP3 had a significantly lower 3-year regional recurrence-free survival (RRFS) than did patients with low FOXP3 (49.3% vs. 87.3%, univariate log rank p = 0.000). A low CD4/FOXP3 ratio (68.4% vs. 93.7%, univariate log rank p = 0.002) was significantly unfavorable prognostic factors for 3-year distant metastasis-free survival (DMFS). In addition to clinicopathological characteristics, TIL markers represent prognosticators for clinical outcomes.
- 28 August 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 1-8
Open AccessPrognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer
Our aim was to investigate the prognostic significance of tumor-infiltrating lymphocytes (TILs) in operable tongue cancer patients. The presence of CD3+, CD4+, CD8+, and forkhead box protein P3-positive (FOXP3+) TILs in tumor tissues obtained from 93 patients during surgery was examined using immunohistochemistry. The 3-year overall survival (OS) of patients with a low CD8/FOXP3 ratio was significantly lower than that of patients with a high CD8/FOXP3 ratio (63.8% vs. 87.3%, p = 0.001). Patients with high FOXP3 had a significantly lower 3-year regional recurrence-free survival (RRFS) than did patients with low FOXP3 (49.3% vs. 87.3%, univariate log rank p = 0.000). A low CD4/FOXP3 ratio (68.4% vs. 93.7%, univariate log rank p = 0.002) was significantly unfavorable prognostic factors for 3-year distant metastasis-free survival (DMFS). In addition to clinicopathological characteristics, TIL markers represent prognosticators for clinical outcomes.
- 1 November 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 125 (2) , 248-257
The extent of edema and tumor synchronous invasion into the subventricular zone and corpus callosum classify outcomes and radiotherapy strategies of glioblastomas
- 1 November 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 125 (2) , 248-257
The extent of edema and tumor synchronous invasion into the subventricular zone and corpus callosum classify outcomes and radiotherapy strategies of glioblastomas